X-Message-Number: 12268
Date: Mon, 16 Aug 1999 15:12:02 -0700 (PDT)
From: Doug Skrecky <>
Subject: methylcobalamin helps ALS

  The Life Extension Foundation has become interested in methylcobalamin
for a variety of reasons. Here's another:

---------- Forwarded message ----------

  Kaji R.  Kodama M.  Imamura A.  Hashida T.  Kohara N.  Ishizu M.  Inui K. 
  Kimura J.
  Department of Neurology, Kyoto University School of Medicine, Japan.
  Effect of ultrahigh-dose methylcobalamin on
  compound muscle action potentials in amyotrophic lateral sclerosis: a
  double-blind controlled study.
  Muscle & Nerve.  21(12):1775-8, 1998 Dec.
  To develop a symptomatic treatment for amyotrophic lateral sclerosis, we
  compared the effects of ultrahigh-dose and
  low-dose (25 and 0.5 mg/day, intramuscularly, for 14 days) methylcobalamin on
  averaged compound muscle action potential amplitudes (CMAPs) in a
  double-blind trial. No significant changes in CMAP amplitude were found in 12
  patients who had the low-dose treatment at either 2 or 4 weeks after start of
  treatment. By contrast, 12 patients assigned to the
  ultrahigh-dose group demonstrated a significant increase at
  4 weeks. This method may provide a clinically useful measure to improve or
  retard muscle wasting, if a larger extended trial fulfills its promise.

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=12268